keyword
MENU ▼
Read by QxMD icon Read
search

colorectal stage II oxaliplatin

keyword
https://www.readbyqxmd.com/read/28668898/clinical-study-on-the-medical-value-of-combination-therapy-involving-adoptive-immunotherapy-and-chemotherapy-for-stage-iv-colorectal-cancer-comvi-study
#1
Yoichiro Yoshida, Masayasu Naito, Teppei Yamada, Naoya Aisu, Daibo Kojima, Toshiyuki Mera, Toshihiro Tanaka, Keiko Naito, Kosei Yasumoto, Takashi Kamigaki, Shigenori Gotoh, Shohta Kodama, Yuichi Yamashita, Suguru Hasegawa
BACKGROUND: Adoptive immunotherapy for cancer has evolved through development of novel technologies for generating a large number of activated killer cells, such as αβ T-cells, γδ T-cells, and natural killer cells. There has been no prospective trial of combination therapy involving adoptive immunotherapy and first-line chemotherapy for stage IV colorectal cancer. The present pilot study aimed to evaluate the safety and feasibility of combination therapy involving adoptive immunotherapy and chemotherapy for stage IV colorectal cancer (COMVI study)...
July 2017: Anticancer Research
https://www.readbyqxmd.com/read/28668762/mangafodipir-a-selective-cytoprotectant-with-special-reference-to-oxaliplatin-and-its-association-to-chemotherapy-induced-peripheral-neuropathy-cipn
#2
REVIEW
Jan Olof G Karlsson, Rolf Gg Andersson, Per Jynge
Oxaliplatin, in combination with 5-fluorouracil plus folinate (or capecitabine), has increased survival substantially in stage III colorectal cancer and prolonged life in stage IV patients, but its use is compromised because of severe toxicity. Chemotherapy-induced peripheral neuropathy (CIPN) is the most problematic dose-limiting toxicity of oxaliplatin. Oncologists included for years calcium and magnesium infusion as part of clinical practice for preventing CIPN. Results from a phase III prospective study published in 2014, however, overturned this practice...
August 2017: Translational Oncology
https://www.readbyqxmd.com/read/28653974/hla-g-3-utr-polymorphisms-predict-drug-induced-g3-4-toxicity-related-to-folinic-acid-5-fluorouracil-oxaliplatin-folfox4-chemotherapy-in-non-metastatic-colorectal-cancer
#3
Marica Garziera, Saverio Virdone, Elena De Mattia, Lucia Scarabel, Erika Cecchin, Jerry Polesel, Mario D'Andrea, Nicoletta Pella, Angela Buonadonna, Adolfo Favaretto, Giuseppe Toffoli
Polymorphisms in drug-metabolizing enzymes might not completely explain inter-individual differences in toxicity profiles of patients with colorectal cancer (CRC) that receive folinic acid/5-fluorouracil/oxaliplatin (FOLFOX4). Recent data indicate that the immune system could contribute to FOLFOX4 outcomes. In light of the immune inhibitory nature of human leukocyte antigen-G (HLA-G), a non-classical major histocompatibility complex (MHC) class I molecule, we aimed to identify novel genomic markers of grades 3 and 4 (G3-4) toxicity related to FOLFOX4 therapy in patients with CRC...
June 27, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28589428/annual-hazard-rate-of-relapse-of-stage-ii-and-iii-colorectal-cancer-after-primary-therapy
#4
N Mejri, M Dridi, S Labidi, H El Benna, N Daoud, H Boussen
PURPOSE: To report the annual hazard of relapse in stages II and III colorectal cancer (CRC) Tunisian patients treated with curative intent. We also aim to evaluate impact of oxaliplatine according to anatomo-clinical features. METHODS: We collected data about clinico-pathological parameters of 331 CRCs. We analyzed annual hazard of recurrence (locoregional and/or distant) of the overall population and several subgroups: colon cancer vs rectal cancer and stage II vs stage III...
June 6, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/28515931/pharmaco-economic-analysis-of-adjuvant-chemotherapy-for-stage-ii-and-iii-colorectal-cancer
#5
Mina Iwai, Michio Kimura, Eiseki Usami, Tomoaki Yoshimura, Hitomi Teramachi
Comparison of the costs of capecitabine plus oxaliplatin (CapeOX) with that of FOLFOX6 (5-fluorouracil/leucovorin [LV] + oxaliplatin) as an adjuvant chemotherapy for stage II or III colorectal cancer has previously been reported. However, there are no reports comparing uracil and tegafur (UFT)/LV with capecitabine. Therefore, the current study compared the costs of adjuvant chemotherapy regimens including CapeOX, FOLFOX6, capecitabine and UFT/LV. The costs of chemotherapeutic drugs and for the prevention and treatment of adverse events were evaluated, as these account for the bulk of the treatment costs...
May 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28513830/association-between-mutations-of-critical-pathway-genes-and-survival-outcomes-according-to-the-tumor-location-in-colorectal-cancer
#6
Dae-Won Lee, Sae-Won Han, Yongjun Cha, Jeong Mo Bae, Hwang-Phill Kim, Jaemyun Lyu, Hyojun Han, Hyoki Kim, Hoon Jang, Duhee Bang, Iksoo Huh, Taesung Park, Jae-Kyung Won, Seung-Yong Jeong, Kyu Joo Park, Gyeong Hoon Kang, Tae-You Kim
BACKGROUND: Colorectal cancer (CRC) develops through the alteration of several critical pathways. This study was aimed at evaluating the influence of critical pathways on survival outcomes for patients with CRC. METHODS: Targeted next-generation sequencing of 40 genes included in the 5 critical pathways of CRC (WNT, P53, RTK-RAS, phosphatidylinositol-4,5-bisphosphate 3-kinase [PI3K], and transforming growth factor β [TGF-β]) was performed for 516 patients with stage III or high-risk stage II CRC treated with surgery followed by adjuvant fluoropyrimidine and oxaliplatin chemotherapy...
May 17, 2017: Cancer
https://www.readbyqxmd.com/read/28434884/neurotoxicity-outcomes-in-a-population-based-cohort-of-elderly-patients-treated-with-adjuvant-oxaliplatin-for-colorectal-cancer
#7
Michael J Raphael, Hadas D Fischer, Kinwah Fung, Peter C Austin, Geoffrey M Anderson, Christopher M Booth, Simron Singh
BACKGROUND: The addition of oxaliplatin to adjuvant treatment regimens for colorectal cancer has been shown to improve overall survival at the expense of increased toxicity. The incidence and severity of toxicity might be greater among older patients who might also derive less benefit from oxaliplatin. We evaluated the association between adjuvant oxaliplatin-based chemotherapy and neurotoxicity outcomes in an elderly cohort of patients. PATIENTS AND METHODS: A population-based cohort of patients aged > 65 years with stage II and III colorectal cancer treated with adjuvant therapy in Ontario, Canada was identified using the Ontario Cancer Registry...
March 24, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28383445/anorectal-function-and-quality-of-life-in-patients-with-early-stage-rectal-cancer-treated-with-chemoradiation-and-local-excision
#8
MULTICENTER STUDY
Patricio B Lynn, Lindsay A Renfro, Xiomara W Carrero, Qian Shi, Paul L Strombom, Oliver Chow, Julio Garcia-Aguilar
BACKGROUND: Little is known about anorectal function and quality of life after chemoradiation followed by local excision, which is an alternative to total mesorectal excision for selected patients with early rectal cancer. OBJECTIVE: The purpose of this study was to prospectively assess anorectal function and health-related quality of life of patients with T2N0 rectal cancer who were treated with an alternative approach. DESIGN: This was a prospective, phase II trial...
May 2017: Diseases of the Colon and Rectum
https://www.readbyqxmd.com/read/28356150/pregnane-x-receptor-is-associated-with-unfavorable-survival-and-induces-chemotherapeutic-resistance-by-transcriptional-activating-multidrug-resistance-related-protein-3-in-colorectal-cancer
#9
Yan Dong, Zhe Wang, Gan-Feng Xie, Chong Li, Wen-Wei Zuo, Gang Meng, Cheng-Ping Xu, Jian-Jun Li
BACKGROUND: Although chemotherapy represents a predominant anti-cancer therapeutic modality, drug treatment efficacy is often limited due to the development of resistant tumor cells. The pregnane X receptor (PXR) affects chemotherapeutic effects by regulating targets involved in drug metabolism and transportation, but the regulatory mechanism is poorly understood. METHODS: Oxaliplatin (L-OHP) content in tumor cells was analyzed by mass cytometry. The roles of PXR on cancer cell proliferation, apoptosis and tumor growth with L-OHP-treated were investigated by MTS, colony formation, flow cytometry and xenograft tumor assays...
March 29, 2017: Molecular Cancer
https://www.readbyqxmd.com/read/28284575/mfolfox6-plus-panitumumab-versus-5-fu-lv-plus-panitumumab-after-six-cycles-of-frontline-mfolfox6-plus-panitumumab-a-randomized-phase-ii-study-of-patients-with-unresectable-or-advanced-recurrent-ras-wild-type-colorectal-carcinoma-sapphire-study-design-and%C3%A2-rationale
#10
Naoki Nagata, Hideyuki Mishima, Shuichi Kurosawa, Koji Oba, Junichi Sakamoto
BACKGROUND: In Japan, oxaliplatin (OXA)/5-fluorouracil (5-FU)/leucovorin (LV)-the mFOLFOX6 regimen-is the most frequently used first-line chemotherapy backbone for metastatic colorectal cancer. However, peripheral nerve disorders caused by OXA during mFOLFOX6 therapy can decrease patients' quality of life. OXA can be safely discontinued from a FOLFOX regimen after 6 cycles during first-line therapy. Also, for patients who discontinue OXA without having experienced peripheral nerve disorders, reintroducing OXA in the later stages of treatment could remain an option...
March 1, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28278514/distinct-clinical-outcomes-of-two-cimp-positive-colorectal-cancer-subtypes-based-on-a-revised-cimp-classification-system
#11
Jeong Mo Bae, Jung Ho Kim, Yoonjin Kwak, Dae-Won Lee, Yongjun Cha, Xianyu Wen, Tae Hun Lee, Nam-Yun Cho, Seung-Yong Jeong, Kyu Joo Park, Sae Won Han, Hye Seung Lee, Tae-You Kim, Gyeong Hoon Kang
BACKGROUND: Colorectal cancer (CRC) is a heterogeneous disease in terms of molecular carcinogenic pathways. Based on recent findings regarding the multiple serrated neoplasia pathway, we revised an eight-marker panel for a new CIMP classification system. METHODS: 1370 patients who received surgical resection for CRCs were classified into three CIMP subtypes (CIMP-N: 0-4 methylated markers, CIMP-P1: 5-6 methylated markers and CIMP-P2: 7-8 methylated markers). Our findings were validated in a separate set of high-risk stage II or stage III CRCs receiving adjuvant fluoropyrimidine plus oxaliplatin (n=950)...
April 11, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28079003/colorectal-cancer-chemotherapy-the-evolution-of-treatment-and-new-approaches
#12
Rachel M McQuade, Vanesa Stojanovska, Joel C Bornstein, Kulmira Nurgali
Colorectal cancer (CRC) is one the greatest contributors to cancer related mortality. Although 5 year survival rate for patients at the early stage of CRC (stages I and II) is above 60%, more than 50% of patients are diagnosed at or beyond stage III when distant metastasis has already occurred, in which case 5 year survival rate drops to 10%. Chemotherapeutic intervention coupled with surgery is the backbone of metastatic CRC treatment and the only means of enhanced survival. For decades following its discovery, an antimetabolite 5-fluorouracil (5-FU) was the only chemotherapeutic agent available to successfully improve 12 month survival in CRC patients...
January 11, 2017: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/27979717/perioperative-triplet-chemotherapy-and-cetuximab-in-patients-with-ras-wild-type-high-recurrence-risk-or-borderline-resectable-colorectal-cancer-liver-metastases
#13
Filippo Pietrantonio, Maria Di Bartolomeo, Christian Cotsoglou, Alessia Mennitto, Rosa Berenato, Federica Morano, Jorgelina Coppa, Federica Perrone, Roberto Iacovelli, Massimo Milione, Alessandra Alessi, Marta Vaiani, Ilaria Bossi, Francesca Ricchini, Mauro Scotti, Marta Caporale, Emilio Bajetta, Filippo de Braud, Vincenzo Mazzaferro
BACKGROUND: For borderline resectable colorectal cancer liver metastases (CLM), systemic treatment can help to achieve R0 resection and reduce the risk of relapse. We assessed the role of perioperative triplet chemotherapy in combination with cetuximab in patients with RAS wild type high recurrence risk and/or borderline resectable CLM. PATIENTS AND METHODS: This was a monocenter, open-label phase II study. Borderline resectability was defined technically as tumor involvement of >1 hepatic vein, or >4 hepatic segments, need for 2-stage hepatectomy or radiofrequency ablation, and/or biologically (high risk): ≥4 metastatic nodules, or synchronous metastases...
October 6, 2016: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/27920498/feasibility-of-sequential-adjuvant-chemotherapy-with-a-3-month-oxaliplatin-based-regimen-followed-by-3-months-of-capecitabine-in-patients-with-stage-iii-and-high-risk-stage-ii-colorectal-cancer-jswog-c2-study
#14
MULTICENTER STUDY
Atsushi Tsuruta, Kazuki Yamashita, Hiroaki Tanioka, Akihito Tsuji, Michio Inukai, Toshiki Yamakawa, Tomoki Yamatsuji, Masanori Yoshimitsu, Kazuhiro Toyota, Taketoshi Yamano, Takeshi Nagasaka, Masazumi Okajima
BACKGROUND: Six months of oxaliplatin-based chemotherapy is the standard adjuvant chemotherapy for completely resected stage III colorectal cancer (CRC). Also, patients with stage II CRC who are considered to be at high risk of disease recurrence often receive the same adjuvant chemotherapy treatment. We prospectively investigated the extent and degree of neuropathy suffered by stage III and high-risk stage II resectable CRC patients who underwent sequential approach involving 3 months of an oxaliplatin-based regimen followed by 3 months of capecitabine...
2016: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/27900205/efficacy-and-toxicity-of-adjuvant-chemotherapy-in-elderly-patients-with-colorectal-cancer-the-accore-study
#15
C M Lund, D Nielsen, C Dehlendorff, A B Christiansen, F Rønholt, J S Johansen, K K Vistisen
BACKGROUND: Elderly patients with primary colorectal cancer (CRC) are less frequently treated with adjuvant chemotherapy than younger patients due to concerns regarding toxicity and efficiency. We investigated how age, performance status (PS) and comorbidity influence treatment outcomes. PATIENTS AND METHODS: A retrospective single-centre study of 529 patients with stages II-III CRC treated with adjuvant chemotherapy (5-fluorouracil/capecitabine+/÷oxaliplatin) from 2001 to 2011 at Herlev Hospital, Denmark...
2016: ESMO Open
https://www.readbyqxmd.com/read/27341598/adjuvant-therapy-trials
#16
REVIEW
Carling Ursem, Katherine Van Loon, Alan Venook
In 2015, ramucirumab and TAS-102 became the 10th and 11th drugs approved by the Food and Drug administration for the treatment of patients with colorectal cancer, not counting leucovorin, and yet only 3 agents, 5-fluorouracil, capecitabine, and oxaliplatin, have proven benefit in adjuvant treatment. In fact, there have been no additions (and 1 subtraction levamisole) to our arsenal of therapies for patients with stages II and III colon cancer for more than a decade. How did we get here? Are we stuck? And how do we move forward?...
May 2016: Cancer Journal
https://www.readbyqxmd.com/read/27270348/clinical-outcome-from-oxaliplatin-treatment-in-stage-ii-iii-colon-cancer-according-to-intrinsic-subtypes-secondary-analysis-of-nsabp-c-07-nrg-oncology-randomized-clinical-trial
#17
RANDOMIZED CONTROLLED TRIAL
Nan Song, Katherine L Pogue-Geile, Patrick G Gavin, Greg Yothers, S Rim Kim, Nicole L Johnson, Corey Lipchik, Carmen J Allegra, Nicholas J Petrelli, Michael J O'Connell, Norman Wolmark, Soonmyung Paik
IMPORTANCE: Oxaliplatin added to fluorouracil plus leucovorin therapy for patients with colon cancer has been shown to provide significant but modest absolute benefit for disease-free survival. However, acute and chronic neurotoxic effects from this regimen underscore the need for markers that predict oxaliplatin benefit. OBJECTIVE: To test our hypothesis that molecular subtypes of colon cancer would be associated with differential prognosis and benefit from oxaliplatin added to fluorouracil plus leucovorin therapy...
September 1, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/27155613/phase-1-study-on-s-1-and-oxaliplatin-therapy-as-an-adjuvant-after-hepatectomy-for-colorectal-liver-metastases
#18
Michiro Takahashi, Kiyoshi Hasegawa, Masaru Oba, Akio Saiura, Junichi Arita, Yoshihiro Sakamoto, Eiji Shinozaki, Nobuyuki Mizunuma, Yutaka Matsuyama, Norihiro Kokudo
of Background Data The effectiveness of adjuvant chemotherapy in patients with stage II/III colorectal cancer has been confirmed in various studies. However, no adjuvant chemotherapy for colorectal liver metastasis (CLM) classified to stage IV has been established. Objectives We conducted a phase 1 study of S-1 and oxaliplatin to determine the recommended dose (RD) in patients with CLM as adjuvant therapy in two institutes. Methods S-1 and oxaliplatin were administered from day 1 to day 14 of a 3-week cycle as a 2-h infusion every 3 weeks, respectively...
August 2016: Investigational New Drugs
https://www.readbyqxmd.com/read/27051466/associations-and-prognostic-implications-of-eastern-cooperative-oncology-group-performance-status-and-tumoral-line-1-methylation-status-in-stage-iii-colon-cancer-patients
#19
Duo Chen, Xianyu Wen, Young Seok Song, Ye-Young Rhee, Tae Hun Lee, Nam Yun Cho, Sae-Won Han, Tae-You Kim, Gyeong Hoon Kang
BACKGROUND: Low methylation status of LINE-1 in tumors is associated with poor survival in patients with colon cancer. Eastern Cooperative Oncology Group performance status (ECOG-PS) is a method to assess the functional status of a patient. We retrospectively evaluated the relationship between ECOG-PS and LINE-1 methylation in colorectal cancers (CRCs) and their prognostic impact in CRC or colon cancer patients receiving adjuvant 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX). RESULTS: LINE-1 methylation and microsatellite instability were analyzed in stage III or high-risk stage II CRCs (n = 336)...
2016: Clinical Epigenetics
https://www.readbyqxmd.com/read/26992409/the-trajectory-of-neurotoxic-side-effects-impact-on-daily-life-a-qualitative-study
#20
Jenny Drott, Hans Starkhammar, Karin Kjellgren, Carina Berterö
PURPOSE: The purpose of this study was to explore the experiences of oxaliplatin-induced neurotoxic side effects among patients with colorectal cancer (CRC) and how these side effects influenced their daily lives over time. METHODS: To assess neurotoxic side effects, ten patients were repeatedly interviewed. The patients were recruited from two hospitals in south of Sweden, had stage II-III CRC, and had been treated with adjuvant oxaliplatin postoperatively, from November 2013 to October 2015...
August 2016: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
keyword
keyword
102640
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"